Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	Oliena Studio Stroke and language recovery: 9000+ videos Español • Italiano • Sardu • English | PDF+

Breast Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 159 articles: HTML format Text format

Single Articles

June 2019
1. DASHTI SG, Simpson JA, Karahalios A, Viallon V, et al
   Adiposity and estrogen receptor-positive, postmenopausal breast cancer risk: quantification of the mediating effects of fasting insulin and free estradiol.
   Int J Cancer. 2019 Jun 12. doi: 10.1002/ijc.32504.
   PubMed     Text format     Abstract available
   
   
   
2. CYBULSKI C, Kluzniak W, Huzarski T, Wokolorczyk D, et al
   The Spectrum of Mutations Predisposing to Familial Breast Cancer in Poland.
   Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32492.
   PubMed     Text format     Abstract available
   
   
   
3. WANG S, Pitt JJ, Zheng Y, Yoshimatsu TF, et al
   Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria.
   Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32498.
   PubMed     Text format     Abstract available
   
   
   
4. AN KY, Morielli AR, Kang DW, Friedenreich CM, et al
   Effects of exercise dose and type during breast cancer chemotherapy on longer-term patient-reported outcomes and health-related fitness: A randomized controlled trial.
   Int J Cancer. 2019 Jun 7. doi: 10.1002/ijc.32493.
   PubMed     Text format     Abstract available
   
   
   
5. GLUZ O, Kolberg-Liedtke C, Prat A, Christgen M, et al
   Efficacy of de-escalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
   Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32488.
   PubMed     Text format     Abstract available
   
   
   May 2019
6. SHENG S, Xu Y, Guo Y, Yao L, et al
   Prevalence and Clinical Impact of TP53 Germline Mutations in Chinese Women with Breast Cancer.
   Int J Cancer. 2019 May 21. doi: 10.1002/ijc.32424.
   PubMed     Text format     Abstract available
   
   
   
7. LI G, Xie Q, Yang Z, Wang L, et al
   Sp1-mediated epigenetic dysregulation dictates HDAC inhibitor susceptibility of HER2-overexpressing breast cancer.
   Int J Cancer. 2019 May 21. doi: 10.1002/ijc.32425.
   PubMed     Text format     Abstract available
   
   
   
8. TRAPANI D, Rajasekar AKA, Mathew A
   More options for adjuvant treatment of HER2-positive breast cancer: How to choose wisely?
   Int J Cancer. 2019 May 20. doi: 10.1002/ijc.32418.
   PubMed     Text format     Abstract available
   
   
   
9. RANINGA PV, Lee A, Sinha D, Shih YY, et al
   Therapeutic cooperation between auranofin, a thioredoxin reductase inhibitor and anti-PD-L1 antibody for treatment of triple-negative breast cancer.
   Int J Cancer. 2019 May 15. doi: 10.1002/ijc.32410.
   PubMed     Text format     Abstract available
   
   
   
10. JOKO-FRU WY, Miranda-Filho A, Soerjomataram I, Egue M, et al
    Breast cancer survival in sub-Saharan Africa by age, stage at diagnosis and Human Development Index (HDI): A population-based registry study.
    Int J Cancer. 2019 May 14. doi: 10.1002/ijc.32406.
    PubMed     Text format     Abstract available
    
    
    
11. KUMARAN M, Ghosh S, Joy AA, Mackey JR, et al
    Fine-mapping of a novel premenopausal breast cancer susceptibility locus at Chr4q31.22 in Caucasian women and validation in African and Chinese women.
    Int J Cancer. 2019 May 14. doi: 10.1002/ijc.32407.
    PubMed     Text format     Abstract available
    
    
    
12. JACOT W, Heudel PE, Fraisse J, Gourgou S, et al
    Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
    Int J Cancer. 2019 May 14. doi: 10.1002/ijc.32402.
    PubMed     Text format     Abstract available
    
    
    
13. ENGEL C, Fischer C, Zachariae S, Bucksch K, et al
    Breast cancer risk in BRCA1/2 mutation carriers and non-carriers under prospective intensified surveillance.
    Int J Cancer. 2019 May 13. doi: 10.1002/ijc.32396.
    PubMed     Text format     Abstract available
    
    
    April 2019
14. GE J, Liu H, Qian D, Wang X, et al
    Genetic variants of genes in the NER pathway associated with risk of breast cancer: a large-scale analysis of 14 published GWAS datasets in the DRIVE Study.
    Int J Cancer. 2019 Apr 26. doi: 10.1002/ijc.32371.
    PubMed     Text format     Abstract available
    
    
    
15. FEKETE JT, Gyorffy B
    ROCplot.org: Validating predictive biomarkers of chemotherapy/hormonal therapy/anti-HER2 therapy using transcriptomic data of 3,104 breast cancer patients.
    Int J Cancer. 2019 Apr 24. doi: 10.1002/ijc.32369.
    PubMed     Text format     Abstract available
    
    
    
16. WANG Z, Li Y, Xiao Y, Lin HP, et al
    Integrin alpha9 depletion promotes beta-catenin degradation to suppress triple negative breast cancer tumor growth and metastasis.
    Int J Cancer. 2019 Apr 22. doi: 10.1002/ijc.32359.
    PubMed     Text format     Abstract available
    
    
    
17. MANCINI FR, Cano-Sancho G, Gambaretti J, Marchand P, et al
    Perfluorinated alkylated substances serum concentration and breast cancer risk: Evidence from a nested case-control study in the French E3N cohort.
    Int J Cancer. 2019 Apr 22. doi: 10.1002/ijc.32357.
    PubMed     Text format     Abstract available
    
    
    
18. VERON L, Gelot A, Gusto G, Arveux P, et al
    Modifiable risk factors for advanced versus early breast cancer in the French E3N cohort.
    Int J Cancer. 2019 Apr 19. doi: 10.1002/ijc.32354.
    PubMed     Text format     Abstract available
    
    
    
19. VAN DOOIJEWEERT C, van Diest PJ, Willems SM, Kuijpers CCHJ, et al
    Significant inter- and intra-laboratory variation in grading of invasive breast cancer: a nationwide study of 33,043 patients in the Netherlands.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32330.
    PubMed     Text format     Abstract available
    
    
    
20. XIE G, Yang H, Ma D, Sun Y, et al
    Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
    Int J Cancer. 2019 Apr 11. doi: 10.1002/ijc.32329.
    PubMed     Text format     Abstract available
    
    
    
21. ASSI N, Rinaldi S, Viallon V, Dashti SG, et al
    Mediation analysis of the alcohol-postmenopausal breast cancer relationship by sex hormones in the EPIC Cohort.
    Int J Cancer. 2019 Apr 10. doi: 10.1002/ijc.32324.
    PubMed     Text format     Abstract available
    
    
    
22. LIU LC, Wang YL, Lin PL, Zhang X, et al
    Long non-coding RNA HOTAIR promotes invasion of breast cancer cells through chondroitin sulfotransferase CHST15.
    Int J Cancer. 2019 Apr 9. doi: 10.1002/ijc.32319.
    PubMed     Text format     Abstract available
    
    
    March 2019
23. CHENG I, Tseng C, Wu J, Yang J, et al
    Association between ambient air pollution and breast cancer risk: The Multiethnic Cohort Study.
    Int J Cancer. 2019 Mar 28. doi: 10.1002/ijc.32308.
    PubMed     Text format     Abstract available
    
    
    
24. NABIEVA N, Haberle L, Brucker SY, Janni W, et al
    Preexisting musculoskeletal burden and its development under letrozole treatment in early breast cancer patients.
    Int J Cancer. 2019 Mar 22. doi: 10.1002/ijc.32294.
    PubMed     Text format     Abstract available
    
    
    
25. SHIGESATO M, Kawai Y, Guillermo C, Youkhana F, et al
    Association between sleep duration and breast cancer incidence: The Multiethnic Cohort.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32292.
    PubMed     Text format     Abstract available
    
    
    
26. VARGA Z, Sinn P, Seidman AD
    Comparing the performance of gene expression assays in breast cancer.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32289.
    PubMed     Text format    
    
    
    
27. SUTHERS GK
    Comparing the performance of gene expression assays in breast cancer.
    Int J Cancer. 2019 Mar 20. doi: 10.1002/ijc.32290.
    PubMed     Text format    
    
    
    
28. KIM EY, Chang Y, Lee KH, Yun JS, et al
    Serum concentration of thyroid hormones in abnormal and euthyroid ranges and breast cancer risk: A cohort study.
    Int J Cancer. 2019 Mar 18. doi: 10.1002/ijc.32283.
    PubMed     Text format     Abstract available
    
    
    
29. LI Z, Wang K, Shi Y, Zhang X, et al
    Incidence of second primary malignancy after breast cancer and related risk factors-is breast conserving surgery safe? A nested case-control study.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32259.
    PubMed     Text format     Abstract available
    
    
    
30. ARROYO-CRESPO JJ, Arminan A, Charbonnier D, Deladriere C, et al
    Characterization of Triple-Negative Breast Cancer Preclinical Models Provides Functional Evidence of Metastatic Progression.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32270.
    PubMed     Text format     Abstract available
    
    
    
31. COUSSY F, de Koning L, Lavigne M, Bernard V, et al
    A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32266.
    PubMed     Text format     Abstract available
    
    
    
32. AMADOU A, Praud D, Coudon T, Danjou AMN, et al
    Chronic long-term exposure to cadmium air pollution and breast cancer risk in the French E3N cohort.
    Int J Cancer. 2019 Mar 9. doi: 10.1002/ijc.32257.
    PubMed     Text format     Abstract available
    
    
    
33. GIULIANELLI S, Riggio M, Guillardoy T, Perez Pinero C, et al
    FGF2 Induces Breast Cancer Growth through Ligand-Independent Activation and Recruitment of ERalpha and PRB4 Isoform to MYC Regulatory Sequences.
    Int J Cancer. 2019 Mar 7. doi: 10.1002/ijc.32252.
    PubMed     Text format     Abstract available
    
    
    February 2019
34. JAYASEKARA H, MacInnis RJ, Chamberlain JA, Dite GS, et al
    Mortality after breast cancer as a function of time since diagnosis by estrogen receptor status and age at diagnosis.
    Int J Cancer. 2019 Feb 16. doi: 10.1002/ijc.32214.
    PubMed     Text format     Abstract available
    
    
    
35. MANDRIK O, Zielonke N, Meheus F, Severens JLH, et al
    Systematic reviews as a "lens of evidence": determinants of benefits and harms of breast cancer screening.
    Int J Cancer. 2019 Feb 14. doi: 10.1002/ijc.32211.
    PubMed     Text format     Abstract available
    
    
    
36. NAPOLITANO G, Lynge E, Lillholm M, Vejborg I, et al
    Change in mammographic density across birth cohorts of Dutch breast cancer screening participants.
    Int J Cancer. 2019 Feb 14. doi: 10.1002/ijc.32210.
    PubMed     Text format     Abstract available
    
    
    
37. DE KRUIJFF IE, Sieuwerts AM, Onstenk W, Jager A, et al
    Androgen receptor expression in circulating tumor cells of patients with metastatic breast cancer.
    Int J Cancer. 2019 Feb 13. doi: 10.1002/ijc.32209.
    PubMed     Text format     Abstract available
    
    
    
38. VAN HELLEMOND IEG, Smorenburg CH, Peer PGM, Swinkels ACP, et al
    Assessment and Management of Bone Health in Women with Early Breast Cancer Receiving Endocrine Treatment in the DATA Study.
    Int J Cancer. 2019 Feb 12. doi: 10.1002/ijc.32205.
    PubMed     Text format     Abstract available
    
    
    
39. ZEINOMAR N, Phillips KA, Daly MB, Milne RL, et al
    Benign Breast Disease Increases Breast Cancer Risk Independent of Underlying Familial Risk Profile: Findings from a Prospective Family Study Cohort (ProF-SC).
    Int J Cancer. 2019 Feb 6. doi: 10.1002/ijc.32112.
    PubMed     Text format     Abstract available
    
    
    
40. KIM JY, Lee E, Park K, Jung HH, et al
    Molecular Alterations and Poziotinib Efficacy, a pan-HER inhibitor, in Human Epidermal Growth Factor Receptor 2 (HER2)-positive breast cancers: Combined Exploratory Biomarker Analysis from a Phase II Clinical Trial of Poziotinib for Refractory HER2-po
    Int J Cancer. 2019 Feb 5. doi: 10.1002/ijc.32188.
    PubMed     Text format     Abstract available
    
    
    
41. SUN W, Xu X, Jiang Y, Jin X, et al
    Transcriptome analysis of Luminal Breast Cancer Reveals a Role for LOL in Tumor Progression and Tamoxifen Resistance.
    Int J Cancer. 2019 Feb 5. doi: 10.1002/ijc.32185.
    PubMed     Text format     Abstract available
    
    
    
42. DENG M, Chen HH, Zhu X, Luo M, et al
    Prevalence and clinical outcomes of germline mutations in BRCA1/2 and PALB2 genes in 2769 unselected breast cancer patients in China.
    Int J Cancer. 2019 Feb 5. doi: 10.1002/ijc.32184.
    PubMed     Text format     Abstract available
    
    
    
43. BARNAWI R, Al-Khaldi S, Colak D, Tulbah A, et al
    beta1 Integrin is Essential for Fascin-Mediated Breast Cancer Stem Cell Function and Disease Progression.
    Int J Cancer. 2019 Feb 4. doi: 10.1002/ijc.32183.
    PubMed     Text format     Abstract available
    
    
    January 2019
44. JANNING M, Muller V, Vettorazzi E, Cubas-Cordova M, et al
    Evaluation of soluble carbonic anhydrase IX as predictive marker for efficacy of bevacizumab: a biomarker analysis from the GeparQuinto phase III neoadjuvant breast cancer trial.
    Int J Cancer. 2019 Jan 29. doi: 10.1002/ijc.32163.
    PubMed     Text format     Abstract available
    
    
    
45. CADENAS C, Vosbeck S, Edlund K, Grgas K, et al
    LIPG-promoted lipid storage mediates adaptation to oxidative stress in breast cancer.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32138.
    PubMed     Text format     Abstract available
    
    
    
46. VARGA Z, Sinn P, Seidman AD
    Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score(R) (RS) assay and other genomic assays for early breast cancer.
    Int J Cancer. 2019 Jan 17. doi: 10.1002/ijc.32139.
    PubMed     Text format     Abstract available
    
    
    
47. RIZZOLO P, Zelli V, Silvestri V, Valentini V, et al
    Insight into genetic susceptibility to male breast cancer by multigene panel testing: Results from a multicenter study in Italy.
    Int J Cancer. 2019 Jan 7. doi: 10.1002/ijc.32106.
    PubMed     Text format     Abstract available
    
    
    December 2018
48. VAN HELLEMOND IEG, Vriens IJH, Peer PGM, Swinkels ACP, et al
    Efficacy of Anastrozole after Tamoxifen in Early Breast Cancer Patients with Chemotherapy-Induced Ovarian Function Failure.
    Int J Cancer. 2018 Dec 26. doi: 10.1002/ijc.32093.
    PubMed     Text format     Abstract available
    
    
    
49. SUNG H, Guo C, Li E, Li J, et al
    The relationship between terminal duct lobular unit features and mammographic density among Chinese breast cancer patients.
    Int J Cancer. 2018 Dec 18. doi: 10.1002/ijc.32077.
    PubMed     Text format     Abstract available
    
    
    
50. GRIONI S, Agnoli C, Krogh V, Pala V, et al
    Dietary cadmium and risk of breast cancer subtypes defined by hormone receptor status: a prospective cohort study.
    Int J Cancer. 2018 Dec 4. doi: 10.1002/ijc.32039.
    PubMed     Text format     Abstract available
    
    
    November 2018
51. TORRES D, Lorenzo Bermejo J, Garcia Mesa K, Gilbert M, et al
    Interaction between genetic ancestry and common breast cancer susceptibility variants in Colombian women.
    Int J Cancer. 2018 Nov 28. doi: 10.1002/ijc.32023.
    PubMed     Text format     Abstract available
    
    
    
52. PANDEY K, An HJ, Kim SK, Lee SA, et al
    Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32020.
    PubMed     Text format     Abstract available
    
    
    
53. KLASCHIK K, Hauke J, Neidhardt G, Trankle C, et al
    The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 26. doi: 10.1002/ijc.32016.
    PubMed     Text format    
    
    
    
54. BULANOVA DR, Helenius M, Sokolenko AP, Kuznetsov SG, et al
    Response to: The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers.
    Int J Cancer. 2018 Nov 25. doi: 10.1002/ijc.32013.
    PubMed     Text format    
    
    
    
55. PEREIRA-VEIGA T, Abreu M, Robledo D, Matias-Guiu X, et al
    CTCs-derived xenograft development in a Triple Negative breast cancer case.
    Int J Cancer. 2018 Nov 19. doi: 10.1002/ijc.32001.
    PubMed     Text format     Abstract available
    
    
    
56. YUAN B, Schafferer S, Tang Q, Scheffler M, et al
    A plasma metabolite panel as biomarkers for early primary breast cancer detection.
    Int J Cancer. 2018 Nov 13. doi: 10.1002/ijc.31996.
    PubMed     Text format     Abstract available
    
    
    
57. ASLEH K, Lyck Carstensen S, Tykjaer Jorgensen CL, Burugu S, et al
    Basal biomarkers Nestin and INPP4B predict gemcitabine benefit in metastatic breast cancer: samples from the phase III SBG0102 clinical trial.
    Int J Cancer. 2018 Nov 9. doi: 10.1002/ijc.31969.
    PubMed     Text format     Abstract available
    
    
    
58. MINICOZZI P, Van Eycken L, Molinie F, Innos K, et al
    Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer.
    Int J Cancer. 2018 Nov 8. doi: 10.1002/ijc.31974.
    PubMed     Text format     Abstract available
    
    
    October 2018
59. VAN MAAREN MC, de Munck L, Strobbe LJ, Sonke GS, et al
    10-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study.
    Int J Cancer. 2018 Oct 28. doi: 10.1002/ijc.31914.
    PubMed     Text format     Abstract available
    
    
    
60. SUN L, Sadique Z, Dos-Santos-Silva I, Yang L, et al
    Cost-effectiveness of Breast Cancer Screening Programme for Women in Rural China.
    Int J Cancer. 2018 Oct 27. doi: 10.1002/ijc.31956.
    PubMed     Text format     Abstract available
    
    
    
61. BENS A, Cronin-Fenton D, Dehlendorff C, Jensen MB, et al
    Non-aspirin NSAIDs and contralateral breast cancer risk.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31949.
    PubMed     Text format    
    
    
    
62. JOHANSSON ALV, Trewin CB, Hjerkind KV, Ellingjord-Dale M, et al
    Breast cancer-specific survival by clinical subtype after seven years follow-up of young and elderly women in a nationwide cohort.
    Int J Cancer. 2018 Oct 26. doi: 10.1002/ijc.31950.
    PubMed     Text format     Abstract available
    
    
    
63. HOUGHTON SC, Eliassen AH, Zhang SM, Selhub J, et al
    Plasma B-vitamin and one-carbon metabolites and risk of breast cancer before and after folic acid fortification in the US.
    Int J Cancer. 2018 Oct 22. doi: 10.1002/ijc.31934.
    PubMed     Text format     Abstract available
    
    
    
64. GIRARD E, Eon-Marchais S, Olaso R, Renault AL, et al
    Familial breast cancer and DNA repair genes: insights into known and novel susceptibility genes from the GENESIS study, and implications for multigene panel testing.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31921.
    PubMed     Text format     Abstract available
    
    
    
65. BERRANDOU T, Mulot C, Cordina-Duverger E, Arveux P, et al
    Association of breast cancer risk with polymorphisms in genes involved in the metabolism of xenobiotics and interaction with tobacco smoking: a gene-set analysis.
    Int J Cancer. 2018 Oct 10. doi: 10.1002/ijc.31917.
    PubMed     Text format     Abstract available
    
    
    
66. SHEN Y, Zhang W, Liu J, He J, et al
    Therapeutic Activity of DCC-2036, a Novel Tyrosine Kinase Inhibitor, against Triple-Negative Breast Cancer Patient-Derived Xenografts by Targeting AXL/MET.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31915.
    PubMed     Text format     Abstract available
    
    
    
67. LATTOUF H, Kassem L, Jacquemetton J, Choucair A, et al
    LKB1 regulates PRMT5 activity in breast cancer.
    Int J Cancer. 2018 Oct 5. doi: 10.1002/ijc.31909.
    PubMed     Text format     Abstract available
    
    
    September 2018
68. HARDING C, Pompei F, Burmistrov D, Wilson R, et al
    Long-term relationships between screening rates, breast cancer characteristics, and overdiagnosis in US counties, 1975-2009.
    Int J Cancer. 2018 Sep 28. doi: 10.1002/ijc.31904.
    PubMed     Text format     Abstract available
    
    
    
69. ELANDS RJ, Offermans NS, Simons CC, Schouten LJ, et al
    Associations of adult-attained height and early life energy restriction with postmenopausal breast cancer risk according to estrogen and progesterone receptor status.
    Int J Cancer. 2018 Sep 25. doi: 10.1002/ijc.31890.
    PubMed     Text format     Abstract available
    
    
    
70. PARK YM, Steck SE, Fung TT, Merchant AT, et al
    Higher diet-dependent acid load is associated with risk of breast cancer: Findings from the Sister Study.
    Int J Cancer. 2018 Sep 24. doi: 10.1002/ijc.31889.
    PubMed     Text format     Abstract available
    
    
    
71. HAM SA, Kim E, Yoo T, Lee WJ, et al
    Ligand-activated interaction of PPARdelta with c-Myc governs the tumorigenicity of breast cancer.
    Int J Cancer. 2018 Sep 11. doi: 10.1002/ijc.31864.
    PubMed     Text format     Abstract available
    
    
    
72. KOMEMI O, Epstein Shochet G, Pomeranz M, Fishman A, et al
    Placenta-conditioned extracellular matrix (ECM) activates breast cancer cell survival mechanisms: A key for future distant metastases.
    Int J Cancer. 2018 Sep 8. doi: 10.1002/ijc.31861.
    PubMed     Text format     Abstract available
    
    
    
73. JIN ML, Kim YW, Jin HL, Kang H, et al
    Aberrant expression of SETD1A promotes survival and migration of estrogen receptor alpha-positive breast cancer cells.
    Int J Cancer. 2018 Sep 7. doi: 10.1002/ijc.31853.
    PubMed     Text format     Abstract available
    
    
    
74. FARVID MS, Stern MC, Norat T, Sasazuki S, et al
    Consumption of red and processed meat and breast cancer incidence: a systematic review and meta-analysis of prospective studies.
    Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31848.
    PubMed     Text format     Abstract available
    
    
    
75. LI J, Wen WX, Eklund M, Kvist A, et al
    Prevalence of BRCA1 and BRCA2 pathogenic variants in a large, unselected breast cancer cohort.
    Int J Cancer. 2018 Sep 2. doi: 10.1002/ijc.31841.
    PubMed     Text format     Abstract available
    
    
    August 2018
76. YE L, Li F, Song Y, Yu D, et al
    Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of Triple-Negative Breast Cancer.
    Int J Cancer. 2018 Aug 27. doi: 10.1002/ijc.31766.
    PubMed     Text format     Abstract available
    
    
    
77. MOLLER MH, Lousdal ML, Kristiansen IS, Stovring H, et al
    Effect of organised mammography screening on breast cancer mortality: A population-based cohort study in Norway.
    Int J Cancer. 2018 Aug 25. doi: 10.1002/ijc.31832.
    PubMed     Text format     Abstract available
    
    
    
78. GAUDET MM, Deubler EL, Kelly RS, Diver WR, et al
    Blood Levels of Cadmium and Lead in Relation to Breast Cancer Risk in Three Prospective Cohorts.
    Int J Cancer. 2018 Aug 17. doi: 10.1002/ijc.31805.
    PubMed     Text format     Abstract available
    
    
    
79. PEDERSEN MH, Hood BL, Ehmsen S, Beck HC, et al
    CYPOR is a novel and independent prognostic biomarker of recurrence-free survival in triple-negative breast cancer patients.
    Int J Cancer. 2018 Aug 15. doi: 10.1002/ijc.31798.
    PubMed     Text format     Abstract available
    
    
    
80. CORTESI L, Canossi B, Battista R, Pecchi A, et al
    Breast ultrasonography in the screening protocol for women at hereditary- familial risk of breast cancer: Has the time come to rethink the role of BU according to different risk categories?
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31794.
    PubMed     Text format     Abstract available
    
    
    
81. LEE WH, Chen LC, Lee CJ, Huang CC, et al
    DNA primase polypeptide 1 (PRIM1) involves in estrogen-induced breast cancer formation through activation of the G2/M cell cycle checkpoint.
    Int J Cancer. 2018 Aug 11. doi: 10.1002/ijc.31788.
    PubMed     Text format     Abstract available
    
    
    
82. REUSTLE A, Fisel P, Renner O, Buttner F, et al
    Characterization of the Breast Cancer Resistance Protein (BCRP/ABCG2) in clear cell renal cell carcinoma.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31741.
    PubMed     Text format     Abstract available
    
    
    
83. CHUANG SC, Lin CH, Lu YS, Hsiung CA, et al
    Association of pregnancy and mortality in women diagnosed with breast cancer: A nationwide population based study in Taiwan.
    Int J Cancer. 2018 Aug 2. doi: 10.1002/ijc.31777.
    PubMed     Text format     Abstract available
    
    
    
84. KWOK ZH, Roche V, Chew XH, Fadieieva A, et al
    A non-canonical tumor suppressive role for the long non-coding RNA MALAT1 in colon and breast cancers.
    Int J Cancer. 2018;143:668-678.
    PubMed     Text format     Abstract available
    
    
    
85. OH H, Pfeiffer RM, Falk RT, Horne HN, et al
    Serum insulin-like growth factor (IGF)-I and IGF binding protein-3 in relation to terminal duct lobular unit involution of the normal breast in Caucasian and African American women: The Susan G. Komen Tissue Bank.
    Int J Cancer. 2018;143:496-507.
    PubMed     Text format     Abstract available
    
    
    July 2018
86. BASU P, Selmouni F, Belakhel L, Sauvaget C, et al
    Breast Cancer Screening Program in Morocco: Status of implementation, organization and performance.
    Int J Cancer. 2018 Jul 14. doi: 10.1002/ijc.31749.
    PubMed     Text format     Abstract available
    
    
    
87. CLENDENEN TV, Dorgan J, Zeleniuch-Jacquotte A
    Reply to: Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31728.
    PubMed     Text format    
    
    
    
88. TESCH H, Stoetzer O, Decker T, Kurbacher CM, et al
    Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer: Results of the single-arm, phase IIIB 4EVER trial
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31738.
    PubMed     Text format     Abstract available
    
    
    
89. MCCORMACK V, Febvey-Combes O, Ginsburg O, Dos-Santos-Silva I, et al
    Breast cancer in women living with HIV: A first global estimate.
    Int J Cancer. 2018 Jul 11. doi: 10.1002/ijc.31722.
    PubMed     Text format     Abstract available
    
    
    
90. BLUMENFELD Z
    Anti-Mullerian hormone and breast cancer risk- is the correlation possibly associated with the PCOS?
    Int J Cancer. 2018 Jul 10. doi: 10.1002/ijc.31732.
    PubMed     Text format    
    
    
    
91. LAN B, Ma F, Chen S, Wang W, et al
    Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10 T/T genotype breast cancer patients in China.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31639.
    PubMed     Text format     Abstract available
    
    
    
92. SALEM Y, Yacov N, Propheta-Meiran O, Breitbart E, et al
    Newly Characterized Motile Sperm Domain-Containing Protein 2 Promotes Human Breast Cancer Metastasis.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31665.
    PubMed     Text format     Abstract available
    
    
    
93. FARVID MS, Chen WY, Rosner BA, Tamimi RM, et al
    Fruit and vegetable consumption and breast cancer incidence: Repeated measures over 30 years of follow-up.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31653.
    PubMed     Text format     Abstract available
    
    
    
94. PARK YH, Lee KH, Sohn JH, Lee KS, et al
    A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31651.
    PubMed     Text format     Abstract available
    
    
    
95. VANGANGELT KMH, Tollenaar LSA, van Pelt GW, de Kruijf EM, et al
    The prognostic value of tumor-stroma ratio in tumor-positive axillary lymph nodes of breast cancer patients.
    Int J Cancer. 2018 Jul 6. doi: 10.1002/ijc.31658.
    PubMed     Text format     Abstract available
    
    
    
96. JASKULSKI S, Jung AY, Behrens S, Johnson T, et al
    Circulating enterolactone concentrations and prognosis of postmenopausal breast cancer: Assessment of mediation by inflammatory markers.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31647.
    PubMed     Text format     Abstract available
    
    
    
97. KISO M, Tanaka S, Saji S, Toi M, et al
    Long isoform of VEGF stimulates cell migration of breast cancer by filopodia formation via NRP1/ARHGAP17/Cdc42 regulatory network.
    Int J Cancer. 2018 Jul 4. doi: 10.1002/ijc.31645.
    PubMed     Text format     Abstract available
    
    
    June 2018
98. LIPTON A, Leitzel K, Ali SM, Polimera HV, et al
    High turnover of extracellular matrix reflected by specific protein fragments measured in serum is associated with poor outcomes in two metastatic breast cancer cohorts.
    Int J Cancer. 2018 Jun 20. doi: 10.1002/ijc.31627.
    PubMed     Text format     Abstract available
    
    
    
99. ANDERSEN AP, Samsoe-Petersen J, Oernbo EK, Boedtkjer E, et al
    The net acid extruders NHE1, NBCn1 and MCT4 promote mammary tumor growth through distinct but overlapping mechanisms.
    Int J Cancer. 2018;142:2529-2542.
    PubMed     Text format     Abstract available
    
    
    May 2018
100. VON NEUBECK B, Gondi G, Riganti C, Pan C, et al
     An inhibitory antibody targeting Carbonic Anhydrase XII abrogates chemoresistance and significantly reduces lung metastases in an orthotopic breast cancer model in vivo.
     Int J Cancer. 2018 May 22. doi: 10.1002/ijc.31607.
     PubMed     Text format     Abstract available
     
     
     
101. WU W, Chen F, Cui X, Yang L, et al
     LncRNA NKILA Suppresses TGF-beta-induced Epithelial-Mesenchymal Transition by Blocking NF-kappaB Signaling in Breast Cancer.
     Int J Cancer. 2018 May 15. doi: 10.1002/ijc.31605.
     PubMed     Text format     Abstract available
     
     
     
102. LI J, Jing R, Wei H, Wang M, et al
     Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer.
     Int J Cancer. 2018 May 12. doi: 10.1002/ijc.31601.
     PubMed     Text format     Abstract available
     
     
     
103. TROISI R, Gulbech Ording A, Grotmol T, Glimelius I, et al
     Pregnancy Complications and Subsequent Breast Cancer Risk in the Mother: A Nordic population-based case-control study.
     Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31600.
     PubMed     Text format     Abstract available
     
     
     
104. LA MANNA S, Lee E, Ouzounova M, Di Natale C, et al
     Mimetics of Suppressor of cytokine signalling 3: novel potential therapeutics in triple breast cancer.
     Int J Cancer. 2018 May 11. doi: 10.1002/ijc.31594.
     PubMed     Text format     Abstract available
     
     
     
105. OH E, Kim YJ, An H, Sung D, et al
     Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition.
     Int J Cancer. 2018 May 9. doi: 10.1002/ijc.31585.
     PubMed     Text format     Abstract available
     
     
     
106. FAN C, Zhang J, Ouyang T, Li J, et al
     RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients.
     Int J Cancer. 2018 May 4. doi: 10.1002/ijc.31579.
     PubMed     Text format     Abstract available
     
     
     April 2018
107. BAGLIA ML, Cook LS, Tang MT, Wiggins C, et al
     Alcohol, Smoking, and Risk of Her2-Overexpressing and Triple-Negative Breast Cancer Relative to Estrogen Receptor-Positive Breast Cancer.
     Int J Cancer. 2018 Apr 30. doi: 10.1002/ijc.31575.
     PubMed     Text format     Abstract available
     
     
     
108. CAIRAT M, Fournier A, Murphy N, Biessy C, et al
     Nonsteroidal anti-inflammatory drug use and breast cancer risk in a European prospective cohort study.
     Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31570.
     PubMed     Text format     Abstract available
     
     
     
109. LI J, Wang W, Xia P, Wan L, et al
     Identification of a five-lncRNA signature for predicting the risk of tumor recurrence in breast cancer patients.
     Int J Cancer. 2018 Apr 29. doi: 10.1002/ijc.31573.
     PubMed     Text format     Abstract available
     
     
     
110. AL-AWADHI A, Murray JL, Ibrahim NK
     Developing Anti-HER2 Vaccines: Breast Cancer Experience.
     Int J Cancer. 2018 Apr 25. doi: 10.1002/ijc.31551.
     PubMed     Text format     Abstract available
     
     
     
111. WILKE CM, Braselmann H, Hess J, Klymenko SV, et al
     A genomic copy number signature predicts radiation exposure in post-Chernobyl breast cancer.
     Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31533.
     PubMed     Text format     Abstract available
     
     
     
112. BOCK J, Appenzeller S, Haertle L, Schneider T, et al
     Single CpG hypermethylation, allele methylation errors, and decreased expression of multiple tumor suppressor genes in normal body cells of mutation-negative early-onset and high-risk breast cancer patients.
     Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31526.
     PubMed     Text format     Abstract available
     
     
     
113. SHAFIEE A, McGovern JA, Lahr CA, Meinert C, et al
     Immune System Augmentation via Humanization Using Stem/Progenitor Cells and Bioengineering in a Breast Cancer Model Study.
     Int J Cancer. 2018 Apr 16. doi: 10.1002/ijc.31528.
     PubMed     Text format     Abstract available
     
     
     
114. CAO C, Wu H, Vasilatos SN, Chandran U, et al
     HDAC5-LSD1 Axis Regulates Antineoplastic Effect of Natural HDAC Inhibitor Sulforaphane in Human Breast Cancer Cells.
     Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31419.
     PubMed     Text format     Abstract available
     
     
     
115. NJOR SH, Paci E, Rebolj M
     As you like it: How the same data can support manifold views of overdiagnosis in breast cancer screening.
     Int J Cancer. 2018 Apr 6. doi: 10.1002/ijc.31420.
     PubMed     Text format     Abstract available
     
     
     March 2018
116. ERIKSSON L, Bergh J, Humphreys K, Warnberg F, et al
     Time from breast cancer diagnosis to therapeutic surgery and breast cancer prognosis: A population-based cohort study.
     Int J Cancer. 2018 Mar 31. doi: 10.1002/ijc.31411.
     PubMed     Text format     Abstract available
     
     
     
117. YUE W, Wang J, Atkins KA, Bottalico L, et al
     Effect of a tissue selective estrogen complex (TSEC) on breast cancer: Role of unique properties of conjugated equine estrogen.
     Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31401.
     PubMed     Text format     Abstract available
     
     
     
118. DE MUNCK L, Fracheboud J, de Bock GH, den Heeten GJ, et al
     Is the incidence of advanced-stage breast cancer affected by whether women attend a steady-state screening program?
     Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31388.
     PubMed     Text format     Abstract available
     
     
     
119. GUINTER MA, McLain AC, Merchant AT, Sandler DP, et al
     A dietary pattern based on estrogen metabolism is associated with breast cancer risk in a prospective cohort of postmenopausal women.
     Int J Cancer. 2018 Mar 25. doi: 10.1002/ijc.31387.
     PubMed     Text format     Abstract available
     
     
     
120. GUO W, Key TJ, Reeves GK
     Adiposity and breast cancer risk in postmenopausal women: Results from the UK Biobank prospective cohort.
     Int J Cancer. 2018 Mar 23. doi: 10.1002/ijc.31394.
     PubMed     Text format     Abstract available
     
     
     
121. WRIGHT LB, Schoemaker MJ, Jones ME, Ashworth A, et al
     Breast cancer risk in relation to history of preeclampsia and hyperemesis gravidarum: Prospective analysis in the Generations Study.
     Int J Cancer. 2018 Mar 8. doi: 10.1002/ijc.31364.
     PubMed     Text format     Abstract available
     
     
     
122. ABUBAKAR M, Chang-Claude J, Ali HR, Chatterjee N, et al
     Etiology of hormone receptor positive breast cancer differs by levels of histologic grade and proliferation.
     Int J Cancer. 2018 Mar 1. doi: 10.1002/ijc.31352.
     PubMed     Text format     Abstract available
     
     
     February 2018
123. GATHIRUA-MWANGI WG, Song Y, Monahan P, Champion VL, et al
     Associations of Metabolic syndrome and C-reactive protein with Mortality from total cancer, obesity-linked cancers and Breast Cancer among Women in NHANES III.
     Int J Cancer. 2018 Feb 27. doi: 10.1002/ijc.31344.
     PubMed     Text format     Abstract available
     
     
     
124. LAN B, Ma F, Zhai X, Li Q, et al
     The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population.
     Int J Cancer. 2018 Feb 3. doi: 10.1002/ijc.31291.
     PubMed     Text format     Abstract available
     
     
     January 2018
125. RIAHI A, Radmanesh H, Schurmann P, Bogdanova N, et al
     Exome sequencing and case-control analyses identify RCC1 as a candidate breast cancer susceptibility gene.
     Int J Cancer. 2018 Jan 24. doi: 10.1002/ijc.31273.
     PubMed     Text format     Abstract available
     
     
     
126. BUSUND M, Bugge NS, Braaten T, Waaseth M, et al
     Progestin-Only and Combined Oral Contraceptives and Receptor-Defined Premenopausal Breast Cancer Risk: The Norwegian Women and Cancer Study.
     Int J Cancer. 2018 Jan 19. doi: 10.1002/ijc.31266.
     PubMed     Text format     Abstract available
     
     
     
127. TERVASMAKI A, Mantere T, Hartikainen JM, Kauppila S, et al
     Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer.
     Int J Cancer. 2018 Jan 17. doi: 10.1002/ijc.31259.
     PubMed     Text format     Abstract available
     
     
     
128. JOHN EM, Hines LM, Phipps AI, Koo J, et al
     Reproductive history, breast-feeding and risk of triple negative breast cancer: The Breast Cancer Etiology in Minorities (BEM) Study.
     Int J Cancer. 2018 Jan 13. doi: 10.1002/ijc.31258.
     PubMed     Text format     Abstract available
     
     
     
129. MURTO MO, Artama M, Pukkala E, Visvanathan K, et al
     Breast cancer extent and survival among diabetic women in a Finnish nationwide cohort study.
     Int J Cancer. 2018 Jan 10. doi: 10.1002/ijc.31250.
     PubMed     Text format     Abstract available
     
     
     
130. GE W, Clendenen TV, Afanasyeva Y, Koenig KL, et al
     Circulating Anti-Mullerian Hormone and Breast Cancer Risk: A Study in Ten Prospective Cohorts.
     Int J Cancer. 2018 Jan 8. doi: 10.1002/ijc.31249.
     PubMed     Text format     Abstract available
     
     
     
131. BASU P, Ponti A, Anttila A, Ronco G, et al
     Status of implementation and organization of cancer screening in The European Union Member States-Summary results from the second European screening report.
     Int J Cancer. 2018;142:44-56.
     PubMed     Text format     Abstract available
     
     
     December 2017
132. ANDERSON C, Engel SM, Anders CK, Nichols HB, et al
     Live birth outcomes after adolescent and young adult breast cancer.
     Int J Cancer. 2017 Dec 21. doi: 10.1002/ijc.31227.
     PubMed     Text format     Abstract available
     
     
     
133. CHEN J, Yao Q, Huang M, Wang B, et al
     A Randomized Phase III Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy for Patients with Breast Cancer (CBCRT01).
     Int J Cancer. 2017 Dec 14. doi: 10.1002/ijc.31217.
     PubMed     Text format     Abstract available
     
     
     
134. XIE X, Tan W, Chen B, Huang X, et al
     Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer.
     Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31208.
     PubMed     Text format     Abstract available
     
     
     
135. MA L, Fu Q, Xu B, Zhou H, et al
     Breast cancer-associated mitochondrial DNA haplogroup promotes neoplastic growth via ROS-mediated AKT activation.
     Int J Cancer. 2017 Dec 11. doi: 10.1002/ijc.31207.
     PubMed     Text format     Abstract available
     
     
     
136. DALLASPEZIA S, Cantamessa S, Benedetti F
     Light Therapy and Mood in Breast Cancer.
     Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31188.
     PubMed     Text format    
     
     
     
137. MCKENZIE F, Zietsman A, Galukande M, Anele A, et al
     Drivers of advanced stage at breast cancer diagnosis in the multi-country African Breast Cancer - Disparities in Outcomes (ABC-DO) study.
     Int J Cancer. 2017 Dec 2. doi: 10.1002/ijc.31187.
     PubMed     Text format     Abstract available
     
     
     November 2017
138. LEE KR, Hwang IC, Do Han K, Jung J, et al
     Waist circumference and risk of breast cancer in Korean women: A nationwide cohort study.
     Int J Cancer. 2017 Nov 29. doi: 10.1002/ijc.31180.
     PubMed     Text format     Abstract available
     
     
     
139. HIS M, Le Guelennec M, Mesrine S, Boutron-Ruault MC, et al
     Life course evolution of body size and breast cancer survival in the E3N cohort.
     Int J Cancer. 2017 Nov 27. doi: 10.1002/ijc.31177.
     PubMed     Text format     Abstract available
     
     
     
140. JOHANSSON ALV, Andersson TM, Hsieh CC, Jirstrom K, et al
     Tumor characteristics and prognosis in women with pregnancy-associated breast cancer.
     Int J Cancer. 2017 Nov 23. doi: 10.1002/ijc.31174.
     PubMed     Text format     Abstract available
     
     
     
141. SCHAIRER C, Pfeiffer RM, Gadalla SM
     Autoimmune diseases and breast cancer risk by tumor hormone-receptor status among elderly women.
     Int J Cancer. 2017 Nov 16. doi: 10.1002/ijc.31148.
     PubMed     Text format     Abstract available
     
     
     
142. BRANDT J, Borgquist S, Almgren P, Forsti A, et al
     Thyroid associated genetic polymorphisms in relation to breast cancer risk in the Malmo Diet and Cancer Study.
     Int J Cancer. 2017 Nov 14. doi: 10.1002/ijc.31156.
     PubMed     Text format     Abstract available
     
     
     
143. BARRDAHL M, Canzian F, Gaudet MM, Gapstur SM, et al
     A comprehensive analysis of polymorphic variants in steroid hormone and IGF-1 metabolism and risk of in situ breast cancer: results from the Breast and Prostate Cancer Cohort (BPC3) Consortium.
     Int J Cancer. 2017 Nov 7. doi: 10.1002/ijc.31145.
     PubMed     Text format     Abstract available
     
     
     October 2017
144. SCHMIDT ME, Wiskemann J, Schneeweiss A, Potthoff K, et al
     Determinants of physical, affective, and cognitive fatigue: During breast cancer therapy and 12 months follow-up.
     Int J Cancer. 2017 Oct 30. doi: 10.1002/ijc.31138.
     PubMed     Text format     Abstract available
     
     
     
145. HIRKO KA, Chai B, Spiegelman D, Campos H, et al
     Erythrocyte membrane fatty acids and breast cancer risk: A prospective analysis in the Nurses' Health Study II.
     Int J Cancer. 2017 Oct 26. doi: 10.1002/ijc.31133.
     PubMed     Text format     Abstract available
     
     
     
146. KEINAN-BOKER L, Levine H, Leiba A, Derazne E, et al
     Adolescent obesity and adult male breast cancer in a cohort of 1,382,093 men.
     Int J Cancer. 2017 Oct 21. doi: 10.1002/ijc.31121.
     PubMed     Text format     Abstract available
     
     
     
147. YU J, Wang X, Lu Q, Wang J, et al
     Extracellular 5'-nucleotidase (CD73) promotes human breast cancer cells growth through AKT/GSK-3beta/beta-catenin/cyclinD1 signaling pathway.
     Int J Cancer. 2017 Oct 19. doi: 10.1002/ijc.31112.
     PubMed     Text format     Abstract available
     
     
     
148. SUROWY H, Varga D, Burwinkel B, Marme F, et al
     A low frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early-onset breast cancer (<60 years) and is associated with reduced DNA repair capacity.
     Int J Cancer. 2017 Oct 16. doi: 10.1002/ijc.31105.
     PubMed     Text format     Abstract available
     
     
     
149. ZHAO B, Zhao H
     Impact of clinicopathological characteristics on the efficacy of neoadjuvant therapy in patients with human epidermal growth factor receptor-2-positive breast cancer.
     Int J Cancer. 2017 Oct 11. doi: 10.1002/ijc.31097.
     PubMed     Text format     Abstract available
     
     
     
150. CONRAD C, Gotte M, Schlomann U, Roessler M, et al
     ADAM8 expression in breast cancer derived metastases: Functional implications on MMP-9 expression and transendothelial migration in breast cancer cells.
     Int J Cancer. 2017 Oct 7. doi: 10.1002/ijc.31090.
     PubMed     Text format     Abstract available
     
     
     
151. NAGAPRASHANTHA LD, Adhikari R, Singhal J, Chikara S, et al
     Translational Opportunities for Broad-Spectrum Natural Phytochemicals and Targeted Agent Combinations in Breast Cancer.
     Int J Cancer. 2017 Oct 4. doi: 10.1002/ijc.31085.
     PubMed     Text format     Abstract available
     
     
     September 2017
152. THAPA B, Bahadur Kc R, Uludag H
     Novel Targets for Sensitizing Breast Cancer Cells to TRAIL-Induced Apoptosis with siRNA Delivery.
     Int J Cancer. 2017 Sep 27. doi: 10.1002/ijc.31079.
     PubMed     Text format     Abstract available
     
     
     
153. GUO S, Jing Y, Burcus NI, Lassiter BP, et al
     Nano-Pulse Stimulation Induces Potent Immune Responses, Eradicating Local Breast Cancer while Reducing Distant Metastases.
     Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31071.
     PubMed     Text format     Abstract available
     
     
     
154. WILKE CM, Hess J, Klymenko SV, Chumak VV, et al
     Expression of miRNA-26b-5p and its target TRPS1 is associated with radiation exposure in post-Chernobyl breast cancer.
     Int J Cancer. 2017 Sep 25. doi: 10.1002/ijc.31072.
     PubMed     Text format     Abstract available
     
     
     
155. KIMBUNG S, Markholm I, Bjohle J, Lekberg T, et al
     Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: results from the phase 2 PROMIX trial.
     Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31070.
     PubMed     Text format     Abstract available
     
     
     
156. KORCH C, Hall EM, Dirks WG, Ewing M, et al
     Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
     Int J Cancer. 2017 Sep 22. doi: 10.1002/ijc.31067.
     PubMed     Text format     Abstract available
     
     
     
157. DE GOOIJER MC, Zhang P, Weijer R, Buil LCM, et al
     The impact of P-glycoprotein and Breast Cancer Resistance Protein on the brain pharmacokinetics and pharmacodynamics of a panel of MEK inhibitors.
     Int J Cancer. 2017 Sep 16. doi: 10.1002/ijc.31052.
     PubMed     Text format     Abstract available
     
     
     
158. WANG S, Huo D, Kupfer S, Alleyne D, et al
     Genetic variation in the Vitamin D related pathway and breast cancer risk in women of African ancestry in the Root Consortium.
     Int J Cancer. 2017 Sep 10. doi: 10.1002/ijc.31038.
     PubMed     Text format     Abstract available
     
     
     August 2017
159. CESPEDES FELICIANO EM, Prentice RL, Aragaki AK, Neuhouser ML, et al
     Methodological Considerations for Disentangling a Risk Factor's Influence on Disease Incidence versus Post-Diagnosis Survival: The Example of Obesity and Breast and Colorectal Cancer Mortality in the Women's Health Initiative.
     Int J Cancer. 2017 Aug 18. doi: 10.1002/ijc.30931.
     PubMed     Text format     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: